Mental disorders represent a considerable disease burden, and have a significant impact on the lives of the OECD population, and account for considerable direct and indirect costs. This report argues that even in those OECD countries with a long history of deinstitutionalisation, there is still a long way to go to make community-based mental health care that achieves good outcomes for people with severe mental illness a reality.
English, PDF, 478kb
This country profile describes in details the Canadian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.
English, PDF, 527kb
This country profile describes in details the Australian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.
The OECD Survey on Health System Characteristics is intended to fill gaps in existing information on the institutional features of health systems, to provide input for analyses of health system performance.
This workshop on 11-12 November 2014 in Lausanne, Switzerland will provide an international forum to discuss the challenges and barriers to the development of disease-modifying treatments and diagnostics for Alzheimer’s disease and other dementia.
Elderly individuals with complex, chronic diseases need continuous and tailored care to maintain their health and maximise their ability to participate in society. Japan must change the way it delivers health services for older citizens by strengthening its specialist primary care and making mental health care services more widely available, according to a new OECD report.
The OECD/Korea Policy Centre fosters the exchange of technical information and policy experiences relating to the Asia Pacific region in areas such as health statistics, pension reforms and social policy and expenditure.
Statistics on biotechnology firms, biotechnology R&D (including public sector expenditures), biotech applications and patents.
The Directorate for Science, Technology and Innovation (STI) leads OECD research on the contribution of science, technology and industry to well-being and economic growth. STI Working Papers cover a broad range of topics including definition and measurement of S&T indicators, global value chains, and research on policies to promote innovation.
The detailed analysis of these 10 case studies together with the rest of the analytical text highlight the realities of P4P programs and their potential impact on the performance of health systems in a diversity of settings. This book provides critical insights into the experience to date with P4P and how this tool may be better leveraged to improve health system performance and accountability.